Transcode Raises Ownership Limitation on Series C Preferred Stock to 9.99%

Transcode Therapeutics Inc. amended its Series C Preferred Stock designation to raise the beneficial ownership limitation from 4.99% to 9.99%. This corporate action modifies the terms restricting beneficial ownership on the company's convertible preferred stock.